MA39390A1 - Thérapie génique pour le traitement de la rétinite pigmentaire - Google Patents

Thérapie génique pour le traitement de la rétinite pigmentaire

Info

Publication number
MA39390A1
MA39390A1 MA39390A MA39390A MA39390A1 MA 39390 A1 MA39390 A1 MA 39390A1 MA 39390 A MA39390 A MA 39390A MA 39390 A MA39390 A MA 39390A MA 39390 A1 MA39390 A1 MA 39390A1
Authority
MA
Morocco
Prior art keywords
treatment
retinitis pigmentosa
gene therapy
particles
mir
Prior art date
Application number
MA39390A
Other languages
English (en)
Other versions
MA39390B2 (fr
Inventor
Catherine Oriordan
Matthew Adamowicz
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA39390A1 publication Critical patent/MA39390A1/fr
Publication of MA39390B2 publication Critical patent/MA39390B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour le traitement de la rétinite pigmentaire au moyen de particules d'aav codant mir -708. Dans un aspect de l'invention, des particules virales sont administrées dans l'œil d'un sujet humain, par exemple, par injection sous-rétinienne. Des particules virales comprenant des capsides d'aav5 ou des mutants de ceux-ci sont envisagées.
MA39390A 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire MA39390B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21
PCT/US2015/021896 WO2015143418A2 (fr) 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire

Publications (2)

Publication Number Publication Date
MA39390A1 true MA39390A1 (fr) 2017-12-29
MA39390B2 MA39390B2 (fr) 2022-04-29

Family

ID=52829343

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39390A MA39390B2 (fr) 2014-03-21 2015-03-20 Thérapie génique pour le traitement de la rétinite pigmentaire

Country Status (36)

Country Link
US (3) US10383953B2 (fr)
EP (3) EP3119437B1 (fr)
JP (3) JP6669664B2 (fr)
KR (3) KR20230006039A (fr)
CN (2) CN106456660B (fr)
AR (1) AR099837A1 (fr)
AU (3) AU2015230942B2 (fr)
CA (2) CA2943185C (fr)
CL (1) CL2016002333A1 (fr)
CR (1) CR20160480A (fr)
DK (2) DK3628334T5 (fr)
DO (1) DOP2016000237A (fr)
EA (1) EA201691891A1 (fr)
EC (1) ECSP16083000A (fr)
ES (2) ES2957840T3 (fr)
FI (1) FI3628334T3 (fr)
HR (2) HRP20192141T1 (fr)
HU (2) HUE046454T2 (fr)
IL (3) IL247543B (fr)
LT (2) LT3119437T (fr)
MA (1) MA39390B2 (fr)
MX (2) MX376190B (fr)
MY (2) MY190726A (fr)
NZ (1) NZ724622A (fr)
PE (1) PE20161252A1 (fr)
PH (1) PH12016501684B1 (fr)
PL (2) PL3119437T3 (fr)
PT (2) PT3628334T (fr)
RS (2) RS64611B1 (fr)
SG (3) SG11201607005UA (fr)
SI (2) SI3119437T1 (fr)
TW (2) TWI706789B (fr)
UA (1) UA120050C2 (fr)
UY (1) UY36044A (fr)
WO (1) WO2015143418A2 (fr)
ZA (1) ZA201605924B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3628334T (pt) 2014-03-21 2023-09-26 Genzyme Corp Terapia genética para retinopatia pigmentar
CA3255657A1 (fr) 2015-02-10 2025-12-01 Genzyme Corporation Variant d’arni
US10994026B2 (en) 2015-12-03 2021-05-04 Friedrich Miescher Institute For Biomedical Research SynP160, a promoter for the specific expression of genes in rod photoreceptors
US11059871B2 (en) 2015-12-03 2021-07-13 Friedrich Miescher Institute For Biomedical Research SYNP162, a promoter for the specific expression of genes in rod photoreceptors
JP6966442B2 (ja) * 2015-12-04 2021-11-17 ソルボンヌ・ユニヴェルシテSorbonne Universite プロモーター及びその使用
IL302455A (en) * 2016-03-01 2023-06-01 Univ Florida Adeno-associated virus vectors for the treatment of dominant retinitis pigmentosa
SG10202109385QA (en) * 2016-07-05 2021-10-28 Univ Johns Hopkins Crispr/cas9-based compositions and methods for treating retinal degenerations
CA3056211A1 (fr) * 2017-03-21 2018-09-27 Stylianos MICHALAKIS Therapie genique pour le traitement de la retinite pigmentaire liee a cngb1
MX2020003095A (es) 2017-09-22 2020-10-15 Genzyme Corp Arni variante.
KR20200057051A (ko) * 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
WO2019169333A1 (fr) 2018-03-02 2019-09-06 Sigilon Therapeutics, Inc. Composés afibrotiques, dispositifs et leurs utilisations
EP3759154A1 (fr) 2018-03-02 2021-01-06 Sigilon Therapeutics, Inc. Capsules d'hydrogel biocompatibles et leur procédé de préparation
EP3768327A4 (fr) * 2018-03-23 2022-04-13 The Trustees of Columbia University in the City of New York Édition de gènes pour maladies autosomiques dominantes
CN112203646A (zh) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法
EP3802836A4 (fr) 2018-06-01 2022-10-19 University of Florida Research Foundation, Incorporated Compositions et méthodes pour le traitement de la rétinite pigmentaire dominante
GB201817469D0 (en) 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
AU2020232692A1 (en) * 2019-03-04 2021-09-30 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the AKT pathway
EP3941530A4 (fr) * 2019-03-21 2022-12-14 PTC Therapeutics, Inc. Vecteur et procédé pour traiter le syndrome d'angelman
US12649930B2 (en) 2019-03-27 2026-06-09 Sigilon Therapeutics, Inc. Compositions, devices, and methods for treating Fabry disease
WO2021030745A1 (fr) * 2019-08-15 2021-02-18 The Children's Hospital Of Philadelphia Thérapie par miarn dérivé d'un intron et transgène combinés pour le traitement de sca1
CN115279421A (zh) * 2020-01-10 2022-11-01 坚固生物科技公司 用于联合疗法的病毒载体
WO2021155137A1 (fr) * 2020-01-29 2021-08-05 Genzyme Corporation Protéines de capside de virus adéno-associés modifiés pour thérapie génique oculaire et leurs procédés d'utilisation
CN114521214A (zh) * 2020-07-24 2022-05-20 尔知渃米斯股份有限公司 视紫红质转录体特异性反式剪接核酶及其用途
IL299927A (en) * 2020-07-29 2023-03-01 Univ Florida Improved adeno-associated virus-mediated therapies for X-linked retinoschisis
US20220331241A1 (en) * 2021-04-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Treatment of x-linked juvenile retinoschisis
TWI832531B (zh) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途
WO2024211480A2 (fr) * 2023-04-05 2024-10-10 Genzyme Corporation Thérapie génique ciblée pour la dystrophie myotonique dm-1
CN120098992A (zh) * 2023-12-05 2025-06-06 云舟生物科技(广州)股份有限公司 核酸分子及其作为特异启动子的应用
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP1486567A1 (fr) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vecteur derivé d'un virus associé aux adenovirus pour la thérapie génique
EP2434020B1 (fr) * 2004-01-22 2014-11-05 Dnavec Research Inc. Procédé de production de vecteurs viral de Paramyxoviridae avec l'utilisation d'un promoteur hybride contenant un améliorant de cytomégalovirus et une promoteur de bêta-actine aviaire
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8257969B2 (en) * 2007-04-12 2012-09-04 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
US20090214478A1 (en) 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
AU2010294197C9 (en) 2009-09-10 2018-09-13 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
EP2529020B1 (fr) * 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia Plateforme de fabrication évolutive pour purification de vecteurs viraux et vecteurs viraux ainsi purifiés utilisables en thérapie génique
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
WO2013151664A1 (fr) * 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
CN105120901A (zh) 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
EP2912177A1 (fr) * 2012-10-23 2015-09-02 Cornell University Traitement du cancer du sein métastatique
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
PT3628334T (pt) * 2014-03-21 2023-09-26 Genzyme Corp Terapia genética para retinopatia pigmentar

Also Published As

Publication number Publication date
MX2016012201A (es) 2017-01-19
ZA201605924B (en) 2017-09-27
PT3119437T (pt) 2019-12-12
NZ762841A (en) 2023-11-24
UA120050C2 (uk) 2019-09-25
LT3119437T (lt) 2019-12-27
IL247543A0 (en) 2016-11-30
EP3119437A2 (fr) 2017-01-25
WO2015143418A3 (fr) 2015-11-19
DK3119437T3 (da) 2019-12-09
MY190726A (en) 2022-05-12
CR20160480A (es) 2016-12-14
KR20160127832A (ko) 2016-11-04
CN106456660A (zh) 2017-02-22
AR099837A1 (es) 2016-08-24
SG10201912968WA (en) 2020-02-27
HRP20192141T1 (hr) 2020-02-21
EP3119437B1 (fr) 2019-09-04
WO2015143418A2 (fr) 2015-09-24
SI3628334T1 (sl) 2023-11-30
JP2022084810A (ja) 2022-06-07
MX2020010694A (es) 2020-11-06
IL247543B (en) 2020-07-30
DOP2016000237A (es) 2016-10-16
RS59634B1 (sr) 2020-01-31
EP3628334B1 (fr) 2023-06-28
IL284741B2 (en) 2023-02-01
TW201622752A (zh) 2016-07-01
EP4345165A2 (fr) 2024-04-03
SG11201607005UA (en) 2016-09-29
BR112016021017A2 (pt) 2017-10-03
MX376190B (es) 2025-03-07
AU2021200988B2 (en) 2024-08-01
US12201698B2 (en) 2025-01-21
ECSP16083000A (es) 2017-02-24
KR20250172735A (ko) 2025-12-09
TW202021627A (zh) 2020-06-16
ES2957840T3 (es) 2024-01-26
JP7048563B2 (ja) 2022-04-05
MY203654A (en) 2024-07-11
MA39390B2 (fr) 2022-04-29
PE20161252A1 (es) 2016-11-30
US20200046851A1 (en) 2020-02-13
HUE046454T2 (hu) 2020-03-30
UY36044A (es) 2015-10-30
KR20230006039A (ko) 2023-01-10
EP3628334A1 (fr) 2020-04-01
IL284741A (en) 2021-08-31
TWI780401B (zh) 2022-10-11
PT3628334T (pt) 2023-09-26
PH12016501684A1 (en) 2016-10-03
US20220054657A1 (en) 2022-02-24
EP4345165A3 (fr) 2024-09-25
PL3628334T3 (pl) 2023-12-18
EA201691891A1 (ru) 2017-01-30
AU2015230942A1 (en) 2016-10-13
SG10201808218YA (en) 2018-10-30
HUE063460T2 (hu) 2024-01-28
CA2943185C (fr) 2025-09-16
CA2943185A1 (fr) 2015-09-24
CN115252823A (zh) 2022-11-01
LT3628334T (lt) 2023-09-25
AU2024227776A1 (en) 2024-11-28
ES2760263T3 (es) 2020-05-13
SI3119437T1 (sl) 2020-01-31
AU2021200988A1 (en) 2021-03-11
RS64611B1 (sr) 2023-10-31
AU2015230942B2 (en) 2020-11-19
FI3628334T3 (fi) 2023-09-15
HRP20231077T1 (hr) 2023-12-22
NZ724622A (en) 2022-05-27
JP7534348B2 (ja) 2024-08-14
CL2016002333A1 (es) 2017-05-26
IL275918A (en) 2020-08-31
JP2020059737A (ja) 2020-04-16
US10383953B2 (en) 2019-08-20
US11103598B2 (en) 2021-08-31
US20170173183A1 (en) 2017-06-22
JP2017509632A (ja) 2017-04-06
PH12016501684B1 (en) 2023-03-17
IL284741B (en) 2022-10-01
JP6669664B2 (ja) 2020-03-18
TWI706789B (zh) 2020-10-11
DK3628334T3 (da) 2023-10-02
DK3628334T5 (da) 2024-09-02
CN106456660B (zh) 2022-05-31
IL275918B (en) 2021-07-29
PL3119437T3 (pl) 2020-04-30
CA3254798A1 (fr) 2025-12-01

Similar Documents

Publication Publication Date Title
MA39390B2 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
PH12020550258A1 (en) Trispecific proteins and methods of use
MX2020001187A (es) Composiciones y métodos para la administración de virus adenoasociados.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EP4671369A3 (fr) Traitement de la dmla à l'aide d'un variant d'aav2 avec l'aflibercept
MX2025010483A (es) Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento
EP4600255A3 (fr) Vecteurs aav pour thérapie génique rétinienne et snc
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
EA201790521A1 (ru) Направленная доставка лекарственных веществ, содержащих третичный амин
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2021014338A (es) Particulas virales modificadas y usos de estas.
ZA201701881B (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
EA201890543A1 (ru) Способы и материалы для генной терапии galgt2
PH12020551641A1 (en) Compositions and methods for treating macular dystrophy
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
EP3503928A4 (fr) Méthodes et compositions pour le traitement d'états canins au moyen d'un virus adéno-associé recombinant auto-complémentaire.
EA202191115A1 (ru) Новые пиридазины
EA202191927A1 (ru) Модуляторы gpr35
EA201992109A1 (ru) Способы лечения опосредованных комплементом заболеваний и расстройств
TN2019000238A1 (en) Methods for treating complement-mediated diseases and disorders
EA201990278A1 (ru) Модуляторы соматостатина и их применения
MA39439B2 (fr) Vecteurs aav pour thérapie génique de la rétine et du snc